GlassScriptPhysician profile
Brandon Martin Williams
NPI 1851596068
$6,466.12
in general payments reported to CMS, 2019-2025
30 companies · $1,345 in 2025
The $1,345 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $103 · 2021: $626 · 2022: $502 · 2023: $1,021 · 2024: $2,332 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Travel and Lodging: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.01 |
| Travel and Lodging | $727.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,730.43 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Medtronic, INC. | $1,425.05 | 2021-2025 | Pulseselect, Micra, Telescope |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.58 | 2019-2025 | Lifevest |
| Abbott Laboratories | $373.20 | 2020-2025 | Jot Dx, Cardiomems, Amplatzer Amulet |
| Biosense Webster, INC. | $269.88 | 2022-2024 | Carto 3, Na, Octaray Mapping Catheter |
| E.R. Squibb & Sons, L.L.C. | $178.23 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $130.97 | 2022-2025 | |
| Novo Nordisk INC | $107.29 | 2019-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $90.84 | 2019-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $77.66 | 2019-2024 | Xarelto |
| Cardiva Medical, INC. | $77.24 | 2019-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.89 | 2019-2023 | Jardiance |
| Lundbeck LLC | $57.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $51.05 | 2019 | |
| Philips North America LLC | $48.15 | 2020-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.65 | 2023-2024 | |
| Amgen INC. | $46.69 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $40.16 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.24 | 2023-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $30.78 | 2022-2025 | Onpattro |
| Medtronic Vascular, INC. | $26.70 | 2019 | |
| Amarin Pharma, INC. | $25.66 | 2019 | |
| Irhythm Technologies, INC. | $20.35 | 2020 | |
| Cordis US Corp. | $19.36 | 2025 | Mynx Control Venous |
| Altathera Pharmaceuticals LLC | $17.55 | 2025 | Sotalol Hydrochloride |
| Arbor Pharmaceuticals, INC. | $15.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.20 | 2023 | |
| Bardy Diagnostics, INC. | $14.00 | 2019 | |
| Akcea Therapeutics, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.